Postherpetic Neuralgia Clinical Trial
Official title:
A Phase 4 Multicenter, Open-Label, Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
Verified date | June 2014 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The primary objective is to explore whether sensory symptom cluster analysis is useful for predicting treatment response in Postherpetic Neuralgia.
Status | Terminated |
Enrollment | 9 |
Est. completion date | June 2013 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subjects must have pain present for more than 3 months after the healing of the herpes zoster skin rash. - At screening (V1) and baseline (V2), subjects must have a score of >=4 on the Numeric Rating Scale for Pain (1 week recall period). - At baseline (V2), at least 4 pain diaries must be completed satisfactorily within the last 7 days and the average pain score must be >=4. Exclusion Criteria: - Subjects having other severe pain that may confound assessment or self evaluation of the pain due to PHN. - Neurolytic or neurosurgical therapy for Postherpetic Neuralgia - Skin conditions in the affected dermatome that could alter sensation. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Austria | Pfizer Investigational Site | Senftenberg | A-3541 |
Austria | Pfizer Investigational Site | Wien | |
Germany | Pfizer Investigational Site | Schwerin | |
South Africa | Pfizer Investigational Site | Paarl | Western Cape |
South Africa | Pfizer Investigational Site | Pretoria | Gauteng |
United States | Pfizer Investigational Site | Jekintown | Pennsylvania |
United States | Pfizer Investigational Site | Leesburg | Florida |
United States | Pfizer Investigational Site | Lexington | Kentucky |
United States | Pfizer Investigational Site | Raleigh | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States, Austria, Germany, South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in the Daily Pain Diary (Numerical Rating Scale, NRS) Mean Pain Score at the End of the Study (Week 6). | The numeric rating scale for pain (NRS-Pain) consists of an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain. | Baseline, Week 6 | No |
Secondary | Neuropathic Pain Symptom Inventory (NPSI) at All Visits. | NPSI: participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. | All visits | No |
Secondary | Proportion of Phenotypes Within the 30% and 50% Responder Groups at Baseline and Week 6. | To explore whether sensory symptom cluster analysis is useful for predicting treatment response in paticipants with PHN, identification of the phenotype was initially required of all participants using three different approaches (with or without the baseline PHQ-8, GAD-7 Pain Related Sleep Interference Score Scale, PCS): 1. PainDETECT at baseline, 2. PainPREDICT at baseline, 3. NPSI at baseline. Then for each of the above phenotypes the distribution of the pregabalin responders (using 30% and 50%) were to be compared. | Baseline, Week 6 | No |
Secondary | Patient Global Impression of Change (PGIC) at Week 6/Early Termination. | PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). | Week 6/Early Termination | No |
Secondary | Proportions of Participants With >/=30% and >/=50% Pain Reduction Based on Daily Pain Diary at Baseline and Week 6. | The daily pain diary consists of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants describe their pain during the previous 24 hours by choosing the appropriate number between 0 and 10. Self-assessment is performed daily at bedtime on a telephone via interactive voice response system (IVRS). The endpoint mean pain score is defined as the mean of the last 7 daily diary pain ratings while taking study medication in the open-label phase. Daily pain IVRS diaries were completed daily at bedtime from Visit 1 (Screening) through Visit 7/Early Termination. Participants were asked to complete their first IVRS daily at bedtime on the morning after Visit 1. | Baseline, Week 6 | No |
Secondary | Proportion of Participants Within Each Phenotype Group as Determined by Sensory Symptom Clustering Using the PainPREDICT, PainDETECT and Neuropathic Pain Symptom Inventory at Baseline and Week 6. | To explore whether sensory symptom cluster analysis is useful for predicting treatment response in paticipants with PHN, identification of the phenotype was initially required of all participants using three different approaches (with or without the baseline PHQ-8, GAD-7 Pain Related Sleep Interference Score Scale, PCS): 1. PainDETECT at baseline, 2. PainPREDICT at baseline, 3. NPSI at baseline. | Baseline, Week 6 | No |
Secondary | Patient Health Questionnaire-8 (PHQ-8) at Baseline and Week 6; Generalized Anxiety Disorder-7 (GAD-7) at Screening, Visit 2 (Week 0) and Week 6/Early Termination. | The PHQ-8 is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders. The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as 0 (not at all) to 3 (nearly every day). The PHQ-8 is a validated subset of the PHQ-9, which comprises the first 8 items of the measure. The GAD-7 is a 7-item questionnaire that assesses anxiety. Participants respond as to how each item applies to them on a 4 point response scale. The higher the score, the more severe the anxiety. | Screening, Visit 2 (Week 0) and Week 6/Early Termination | No |
Secondary | Brief Pain Inventory (BPI sf) at Visit 2 (Week 0) and Week 6. | The Brief Pain Inventory-Short Form (BPI-sf) consists of 5 questions. Questions 1, 2, 3, and 4 measure pain on an 11-point scale from 0 (no pain) to 10 (worst pain possible). | Visit 2 (Week 0), Week 6 | No |
Secondary | Patient Catastrophizing Scale (PCS) at Visit 2 (Week 0) and Week 6. | The PCS is a 13-item self report instrument and requires a Grade 6 reading level and has been translated into 12 languages. It instructs participants to reflect on past experience of pain and indicate their experience using a 5-point scale. The PCS was designed for research on catastrophizing and pain experience. Catastrophizing is associated with heightened pain and is "an exaggerated negative mental set brought to bear during actual or anticipated painful experience." It is a multidimensional construct compromising elements of rumination, magnification, and helplessness and its factor structure has been replicated. It has a total score and three subscale scores (score range of 0-52). | Visit 2 (Week 0), Week 6 | No |
Secondary | Pain NRS Score; 1 Week Recall Period. | The numeric rating scale for pain (NRS-Pain) consists of an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain. | 1 Week | No |
Secondary | Short Form 12v2 Health Survey (SF 12v2) at Visit 2 (Week 0), and Week 6/Early Termination. | The Short-Form 12 Health Survey (SF-12v2) is a self-administered, validated questionnaire that measures each of the following 8 health aspects: Physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception over the past week. Higher scores indicate a better health-related quality of life. | Visit 2 (Week 0), and Week 6/Early Termination | No |
Secondary | Change From Baseline to End of the Study (Week 6) in the Daily Sleep Interference Diary (NRS) Mean Pain Score. | The pain-related sleep interference item rating scale is scored on an 11-point numeric rating scale (NRS-Sleep). It is self-administered by the participant in order to rate how pain has interfered with their sleep during the past 24 hours, ranging from 0 (pain does not interfere with sleep) to 10 (completely interferes (unable to sleep due to pain). Participants are to describe how their pain has interfered with their sleep during the past 24 hours by choosing the appropriate number on the numeric rating scale. | Baseline, Week 6 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04546334 -
Erector Spinae Plane Block in Post-herpetic Neuralgia
|
N/A | |
Terminated |
NCT01744522 -
Leech Therapy for Postherpetic Neuralgia
|
N/A | |
Completed |
NCT01688947 -
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00566904 -
New Topical Treatment for Continued Pain After Shingles
|
Phase 1 | |
Completed |
NCT00478179 -
Study of a Bupivacaine Patch (Eladurâ„¢) to Treat Post- Herpetic Neuralgia
|
Phase 2 | |
Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
Completed |
NCT01251211 -
Botulinum Toxin in Peripheral Neuropathic Pain
|
Phase 4 | |
Completed |
NCT01228838 -
Study of NGX-1998 for the Treatment of Postherpetic Neuralgia
|
Phase 2 | |
Completed |
NCT00612105 -
Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
|
Phase 2 | |
Recruiting |
NCT04560361 -
The Analgesic Effect of Electroacupuncture on Postherpetic Neuralgia
|
N/A | |
Recruiting |
NCT05568186 -
Correlation Between Thermal Patterns of Infrared Thermal Imaging and Clinical Phenotype in Patients With Postherpetic Neuralgia
|
||
Recruiting |
NCT04664530 -
The Study on the Esketamine in the Treatment of Postherpetic Neuralgia
|
Phase 4 | |
Active, not recruiting |
NCT01508676 -
Effects of Pennsaid on Clinical Neuropathic Pain
|
N/A | |
Completed |
NCT00885586 -
Acupuncture in Herpes Zoster Neuralgia (ACUZoster)
|
Phase 4 | |
Completed |
NCT00981227 -
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia
|
Phase 2 | |
Completed |
NCT00576108 -
A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00238511 -
An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00007501 -
Shingles Prevention Study
|
Phase 3 | |
Completed |
NCT04594226 -
Electroacupuncture Therapy for Treating Postherpetic Neuralgia
|
N/A | |
Completed |
NCT05140863 -
To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia
|
Phase 3 |